FOLH1 and posterior cortical atrophy: Overall, the aim of the present study was to determine whether exosomal PSMA from the plasma of patients is suitable as a non-invasive biomarker for the diagnosis and prognosis of PCa, and, consequently, as a potential therapeutic agent.